[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-001", "question": "A 74-year-old man presents with heart failure with preserved ejection fraction (HFpEF) and bilateral carpal tunnel syndrome. Echocardiography reveals a granular 'sparkling' appearance of the myocardium and increased wall thickness. A technetium-99m pyrophosphate (PYP) scan shows Grade 3 cardiac uptake (uptake > rib uptake). Serum immunofixation reveals a small IgG lambda monoclonal protein, and serum free light chain ratio is 1.8. Which of the following is the most appropriate next step in management to confirm the diagnosis?", "options": ["Initiate tafamidis therapy", "Perform TTR genetic testing", "Endomyocardial biopsy", "Abdominal fat pad aspiration", "Initiate bortezomib, cyclophosphamide, and dexamethasone"], "answer": "C", "answer_index": 2, "explanation": "While Grade 2/3 PYP uptake is highly specific for ATTR cardiac amyloidosis, this specificity drops significantly in the presence of a monoclonal gammopathy (MGUS). AL amyloidosis can occasionally show uptake on PYP scans. Therefore, in a patient with a positive PYP scan AND a monoclonal protein, a tissue biopsy (endomyocardial is gold standard if non-cardiac biopsy is negative or to avoid sampling error) is mandatory to distinguish ATTR from AL amyloidosis before starting treatment.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 74-year-old with HFpEF, bilateral carpal tunnel syndrome, echo showing granular 'sparkling' myocardium and increased wall thickness (suggestive of infiltrative cardiomyopathy), Grade 3 PYP uptake (highly specific for ATTR-CM), but presence of small IgG lambda monoclonal protein and elevated FLC ratio (1.8) raises concern for AL amyloidosis, necessitating tissue confirmation to distinguish types.\\nMain logical issue(s): None; the stem logically supports endomyocardial biopsy (C) as the definitive next step for confirmation, given high sensitivity in cardiac tissue and to avoid sampling error in non-cardiac sites like fat pad (D), which has low yield (~45%) for wild-type ATTR.\\nMain medical accuracy issue(s): None; aligns with current guidelines (e.g., ASNC/AHA) where positive PYP scan with monoclonal gammopathy requires biopsy to exclude AL before ATTR-specific therapy; echo and scan findings are classic for amyloidosis; treatments (A, E) are premature without typing.\\nMinimal fix: Not needed; item is unambiguous and accurate.\\n\\nBest-answer defensibility: a) Confirming cardiac amyloidosis type in suspected ATTR-CM with coexisting monoclonal gammopathy. b) Discriminating findings: Positive PYP Grade 3 (ATTR-favoring), but M protein/FLC elevation (AL possible); CTS and echo support amyloid. c) Likely ATTR but requires biopsy to rule out AL. d) C fits as gold-standard confirmatory biopsy; assumes direct cardiac sampling needed for reliability. e) A: ATTR treatment premature; B: Genetic for TTR variant post-confirmation; D: Less invasive but lower sensitivity, may not confirm if negative; E: AL treatment without proof.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 74-year-old with HFpEF, bilateral carpal tunnel syndrome, echo showing granular 'sparkling' myocardium and increased wall thickness (suggestive of infiltrative cardiomyopathy), Grade 3 PYP uptake (highly specific for ATTR-CM), but presence of small IgG lambda monoclonal protein and elevated FLC ratio (1.8) raises concern for AL amyloidosis, necessitating tissue confirmation to distinguish types.\nMain logical issue(s): None; the stem logically supports endomyocardial biopsy (C) as the definitive next step for confirmation, given high sensitivity in cardiac tissue and to avoid sampling error in non-cardiac sites like fat pad (D), which has low yield (~45%) for wild-type ATTR.\nMain medical accuracy issue(s): None; aligns with current guidelines (e.g., ASNC/AHA) where positive PYP scan with monoclonal gammopathy requires biopsy to exclude AL before ATTR-specific therapy; echo and scan findings are classic for amyloidosis; treatments (A, E) are premature without typing.\nMinimal fix: Not needed; item is unambiguous and accurate.\n\nBest-answer defensibility: a) Confirming cardiac amyloidosis type in suspected ATTR-CM with coexisting monoclonal gammopathy. b) Discriminating findings: Positive PYP Grade 3 (ATTR-favoring), but M protein/FLC elevation (AL possible); CTS and echo support amyloid. c) Likely ATTR but requires biopsy to rule out AL. d) C fits as gold-standard confirmatory biopsy; assumes direct cardiac sampling needed for reliability. e) A: ATTR treatment premature; B: Genetic for TTR variant post-confirmation; D: Less invasive but lower sensitivity, may not confirm if negative; E: AL treatment without proof.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-002", "question": "A 24-year-old male presents with recurrent fevers, livedo racemosa, and acute left hemiparesis. MRI shows a lacunar infarct in the internal capsule. Angiography reveals a 'beads-on-a-string' appearance in the mesenteric and renal arteries. Laboratory evaluation shows low serum IgM and IgG levels. Genetic testing confirms a biallelic loss-of-function mutation in ADA2. Which of the following is the most appropriate maintenance therapy?", "options": ["Cyclophosphamide", "Rituximab", "Etanercept", "Prednisone monotherapy", "Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "The patient has Deficiency of Adenosine Deaminase 2 (DADA2), which mimics Polyarteritis Nodosa (PAN) but is distinct due to its association with early-onset strokes and hypogammaglobulinemia. Unlike classic PAN, which is treated with cyclophosphamide, DADA2 is driven by TNF-alpha dysregulation. TNF inhibitors (like etanercept) are the treatment of choice and are highly effective in preventing recurrent strokes, whereas cyclophosphamide is often ineffective.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Recurrent fevers, livedo racemosa, acute hemiparesis with lacunar infarct on MRI, 'beads-on-a-string' angiography in mesenteric and renal arteries, low serum IgM and IgG, and confirmed biallelic ADA2 mutation, collectively diagnostic for Deficiency of Adenosine Deaminase 2 (DADA2), a monogenic vasculitis mimicking polyarteritis nodosa (PAN) but with distinct features like early strokes and hypogammaglobulinemia. These clues imply TNF-alpha dysregulation, making TNF inhibition the preferred maintenance therapy.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify etanercept as the single best option without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current guidelines where anti-TNF agents like etanercept are first-line for DADA2 to prevent strokes, while cyclophosphamide is ineffective despite PAN mimicry. Rationale accurately distinguishes DADA2 from classic PAN.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Recurrent fevers, livedo racemosa, acute hemiparesis with lacunar infarct on MRI, 'beads-on-a-string' angiography in mesenteric and renal arteries, low serum IgM and IgG, and confirmed biallelic ADA2 mutation, collectively diagnostic for Deficiency of Adenosine Deaminase 2 (DADA2), a monogenic vasculitis mimicking polyarteritis nodosa (PAN) but with distinct features like early strokes and hypogammaglobulinemia. These clues imply TNF-alpha dysregulation, making TNF inhibition the preferred maintenance therapy.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify etanercept as the single best option without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current guidelines where anti-TNF agents like etanercept are first-line for DADA2 to prevent strokes, while cyclophosphamide is ineffective despite PAN mimicry. Rationale accurately distinguishes DADA2 from classic PAN.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-003", "question": "A 64-year-old male presents with a 1-year history of progressive gait instability, dysarthria, and dysphagia. His wife reports he has severe insomnia, stridor during sleep, and acts out his dreams. Polysomnography confirms obstructive sleep apnea and complex behaviors during both REM and NREM sleep. MRI brain is unremarkable. Which of the following antibodies is most likely to be positive?", "options": ["Anti-Hu", "Anti-Ma2", "Anti-LGI1", "Anti-IgLON5", "Anti-DPPX"], "answer": "D", "answer_index": 3, "explanation": "Anti-IgLON5 disease is a distinct tauopathy characterized by a unique sleep disorder (parasomnias in both REM and NREM sleep, stridor, OSA) combined with bulbar dysfunction and gait instability. While Anti-Ma2 is associated with brainstem/diencephalic involvement and sleepiness, the specific combination of stridor, NREM parasomnias, and bulbar palsy is pathognomonic for Anti-IgLON5.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive gait instability, dysarthria, dysphagia, severe insomnia, sleep stridor, dream enactment, and polysomnography confirming obstructive sleep apnea with complex behaviors in both REM and NREM sleep, alongside unremarkable MRI. These findings collectively point to anti-IgLON5 disease, a tauopathy with characteristic bulbar dysfunction, gait issues, and a unique sleep disorder profile involving parasomnias across sleep stages, stridor, and OSA. The keyed answer D (Anti-IgLON5) fits precisely without requiring unstated assumptions. Alternatives are inferior: A (Anti-Hu) typically involves paraneoplastic sensory neuronopathy without this sleep specificity; B (Anti-Ma2) associates with brainstem involvement and hypersomnolence but lacks stridor and NREM parasomnias; C (Anti-LGI1) features limbic encephalitis with seizures and hyponatremia, not bulbar or gait predominance; E (Anti-DPPX) involves encephalitis with gastrointestinal symptoms and myoclonus, missing the sleep stridor and mixed parasomnias. No main logical issues, as the stem allows clear discrimination of a single best answer without contradictions or underspecification. No main medical accuracy issues; the item's logic aligns with current consensus on anti-IgLON5 encephalopathy, including its tauopathy association and pathognomonic sleep features per major neurological guidelines. Minimal fix: None needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive gait instability, dysarthria, dysphagia, severe insomnia, sleep stridor, dream enactment, and polysomnography confirming obstructive sleep apnea with complex behaviors in both REM and NREM sleep, alongside unremarkable MRI. These findings collectively point to anti-IgLON5 disease, a tauopathy with characteristic bulbar dysfunction, gait issues, and a unique sleep disorder profile involving parasomnias across sleep stages, stridor, and OSA. The keyed answer D (Anti-IgLON5) fits precisely without requiring unstated assumptions. Alternatives are inferior: A (Anti-Hu) typically involves paraneoplastic sensory neuronopathy without this sleep specificity; B (Anti-Ma2) associates with brainstem involvement and hypersomnolence but lacks stridor and NREM parasomnias; C (Anti-LGI1) features limbic encephalitis with seizures and hyponatremia, not bulbar or gait predominance; E (Anti-DPPX) involves encephalitis with gastrointestinal symptoms and myoclonus, missing the sleep stridor and mixed parasomnias. No main logical issues, as the stem allows clear discrimination of a single best answer without contradictions or underspecification. No main medical accuracy issues; the item's logic aligns with current consensus on anti-IgLON5 encephalopathy, including its tauopathy association and pathognomonic sleep features per major neurological guidelines. Minimal fix: None needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-004", "question": "A 68-year-old male presents with fever of unknown origin, 15 kg weight loss, and fatigue 4 years after undergoing aortic valve replacement. Labs reveal pancytopenia and elevated liver enzymes. TTE and TEE show no vegetations. PET-CT demonstrates hypermetabolic activity in the spleen and bone marrow. Bone marrow biopsy reveals non-caseating granulomas. Standard blood cultures are negative. Which of the following is the most likely etiology?", "options": ["Sarcoidosis", "Culture-negative endocarditis (HACEK group)", "Mycobacterium chimaera", "Tropheryma whipplei", "Late-onset prosthetic valve thrombosis"], "answer": "C", "answer_index": 2, "explanation": "This is the classic presentation of disseminated *Mycobacterium chimaera* infection associated with contaminated heater-cooler units used during cardiopulmonary bypass. The incubation period can be several years. It presents with systemic symptoms, cytopenias, and granulomatous inflammation (often misdiagnosed as sarcoidosis). Diagnosis requires specific mycobacterial blood cultures or tissue PCR.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of aortic valve replacement 4 years prior (implying cardiopulmonary bypass exposure), delayed-onset fever of unknown origin, significant weight loss, fatigue, pancytopenia, elevated liver enzymes, absence of vegetations on TTE/TEE, hypermetabolic activity in spleen and bone marrow on PET-CT, non-caseating granulomas on bone marrow biopsy, and negative standard blood cultures. These collectively point to disseminated Mycobacterium chimaera infection from contaminated heater-cooler units, known for long incubation periods and granulomatous inflammation mimicking sarcoidosis. Main logical issue(s): None; the stem provides sufficient discriminating details to identify C as the unique best answer without contradictions or underspecification, as alternatives are less fitting—A (sarcoidosis) lacks surgical link, B (HACEK endocarditis) contradicted by negative echoes, D (Tropheryma whipplei) not surgery-associated, E (thrombosis) inconsistent with systemic granulomas and negative imaging. Main medical accuracy issue(s): None; aligns with established reports of M. chimaera outbreaks post-cardiac surgery, requiring specialized cultures/PCR for diagnosis, consistent with CDC/FDA guidelines and board-level knowledge. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of aortic valve replacement 4 years prior (implying cardiopulmonary bypass exposure), delayed-onset fever of unknown origin, significant weight loss, fatigue, pancytopenia, elevated liver enzymes, absence of vegetations on TTE/TEE, hypermetabolic activity in spleen and bone marrow on PET-CT, non-caseating granulomas on bone marrow biopsy, and negative standard blood cultures. These collectively point to disseminated Mycobacterium chimaera infection from contaminated heater-cooler units, known for long incubation periods and granulomatous inflammation mimicking sarcoidosis. Main logical issue(s): None; the stem provides sufficient discriminating details to identify C as the unique best answer without contradictions or underspecification, as alternatives are less fitting—A (sarcoidosis) lacks surgical link, B (HACEK endocarditis) contradicted by negative echoes, D (Tropheryma whipplei) not surgery-associated, E (thrombosis) inconsistent with systemic granulomas and negative imaging. Main medical accuracy issue(s): None; aligns with established reports of M. chimaera outbreaks post-cardiac surgery, requiring specialized cultures/PCR for diagnosis, consistent with CDC/FDA guidelines and board-level knowledge. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-005", "question": "A 31-year-old female presents with amenorrhea 4 months after a full-term delivery. Ultrasound reveals a 4 cm echogenic mass in the myometrium. Serum beta-hCG is 120 IU/L. Immunohistochemistry of a biopsy specimen shows diffuse positivity for human placental lactogen (hPL) and Ki-67 index of 15%. Staging workup is negative for metastasis. What is the treatment of choice?", "options": ["Methotrexate and Folinic Acid", "Actinomycin D", "EMA-CO regimen", "Hysterectomy", "Pembrolizumab"], "answer": "D", "answer_index": 3, "explanation": "The diagnosis is Placental Site Trophoblastic Tumor (PSTT), distinguished from choriocarcinoma by low beta-hCG, strong hPL positivity, and origin from intermediate trophoblasts. Unlike choriocarcinoma, PSTT is relatively resistant to chemotherapy. For localized (Stage I) disease, hysterectomy is the primary and definitive treatment. Chemotherapy is reserved for metastatic or high-risk disease.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 31-year-old with post-partum amenorrhea, 4 cm myometrial echogenic mass, mildly elevated beta-hCG (120 IU/L), biopsy IHC showing diffuse hPL positivity and Ki-67 15%, negative metastasis staging. These point to placental site trophoblastic tumor (PSTT), characterized by intermediate trophoblast origin, low beta-hCG, hPL expression, and relative chemoresistance. The question asks for treatment of choice in localized (Stage I) disease. Hysterectomy (D) is the definitive therapy per guidelines, as PSTT responds poorly to chemotherapy. Alternatives: A (Methotrexate/Folinic) and B (Actinomycin D) are for low-risk gestational trophoblastic neoplasia (GTN) but ineffective here; C (EMA-CO) is for high-risk GTN/choriocarcinoma, not indicated without metastasis; E (Pembrolizumab) lacks evidence as first-line for PSTT. No main logical issues: stem allows unique discrimination without contradictions or underspecification. No main medical accuracy issues: aligns with NCCN/FIGO standards for PSTT management, emphasizing surgery for non-metastatic cases. Minimal fix: None required; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 31-year-old with post-partum amenorrhea, 4 cm myometrial echogenic mass, mildly elevated beta-hCG (120 IU/L), biopsy IHC showing diffuse hPL positivity and Ki-67 15%, negative metastasis staging. These point to placental site trophoblastic tumor (PSTT), characterized by intermediate trophoblast origin, low beta-hCG, hPL expression, and relative chemoresistance. The question asks for treatment of choice in localized (Stage I) disease. Hysterectomy (D) is the definitive therapy per guidelines, as PSTT responds poorly to chemotherapy. Alternatives: A (Methotrexate/Folinic) and B (Actinomycin D) are for low-risk gestational trophoblastic neoplasia (GTN) but ineffective here; C (EMA-CO) is for high-risk GTN/choriocarcinoma, not indicated without metastasis; E (Pembrolizumab) lacks evidence as first-line for PSTT. No main logical issues: stem allows unique discrimination without contradictions or underspecification. No main medical accuracy issues: aligns with NCCN/FIGO standards for PSTT management, emphasizing surgery for non-metastatic cases. Minimal fix: None required; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-006", "question": "A 40-year-old male with a known diagnosis of Brugada syndrome presents to the ER in electrical storm, having received 4 appropriate ICD shocks for ventricular fibrillation in the past hour. He is currently conscious but anxious. Vital signs are BP 110/70, HR 90. Which pharmacologic agent is most appropriate to suppress the arrhythmia?", "options": ["Intravenous Amiodarone", "Intravenous Lidocaine", "Intravenous Isoproterenol", "Intravenous Procainamide", "Intravenous Metoprolol"], "answer": "C", "answer_index": 2, "explanation": "In Brugada syndrome electrical storm, the goal is to decrease the ST-segment elevation and dispersion. Isoproterenol (a beta-agonist) increases heart rate and calcium current, normalizing the ST segment and suppressing VF. Quinidine is the oral alternative. Amiodarone, beta-blockers, and sodium channel blockers (Procainamide, Lidocaine) are contraindicated or ineffective as they can unmask or exacerbate the Brugada pattern.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 40-year-old male with known Brugada syndrome in electrical storm (4 ICD shocks for VF in past hour), conscious with stable vitals (BP 110/70, HR 90). The question asks for the most appropriate pharmacologic agent to suppress the arrhythmia, implying acute management to prevent recurrent VF. Clues point to need for agent that normalizes ST-segment elevation without exacerbating Brugada pattern.\\nMain logical issue(s), if any: None; the stem provides sufficient details for discrimination—Brugada diagnosis and storm context uniquely favor an agent that increases heart rate and calcium currents, while alternatives are contraindicated or less effective.\\nMain medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ESC recommendations for isoproterenol in Brugada storm to suppress VF by reducing ST elevation). Rationale correctly notes contraindications for sodium channel blockers (lidocaine, procainamide) and beta-blockers (metoprolol), with amiodarone being ineffective or non-preferred. Teaching point is precise and board-relevant.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 40-year-old male with known Brugada syndrome in electrical storm (4 ICD shocks for VF in past hour), conscious with stable vitals (BP 110/70, HR 90). The question asks for the most appropriate pharmacologic agent to suppress the arrhythmia, implying acute management to prevent recurrent VF. Clues point to need for agent that normalizes ST-segment elevation without exacerbating Brugada pattern.\nMain logical issue(s), if any: None; the stem provides sufficient details for discrimination—Brugada diagnosis and storm context uniquely favor an agent that increases heart rate and calcium currents, while alternatives are contraindicated or less effective.\nMain medical accuracy issue(s), if any: None; aligns with current guidelines (e.g., ESC recommendations for isoproterenol in Brugada storm to suppress VF by reducing ST elevation). Rationale correctly notes contraindications for sodium channel blockers (lidocaine, procainamide) and beta-blockers (metoprolol), with amiodarone being ineffective or non-preferred. Teaching point is precise and board-relevant.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-007", "question": "A 32-year-old female presents with subacute confusion, bilateral hearing loss, and visual field deficits. MRI brain shows multiple T2 hyperintense lesions in the corpus callosum ('snowballs') and periventricular white matter. Fluorescein angiography reveals multiple branch retinal artery occlusions (BRAO). CSF shows mild pleocytosis and elevated protein but no oligoclonal bands. What is the most likely diagnosis?", "options": ["Multiple Sclerosis", "CADASIL", "Susac Syndrome", "Primary CNS Angiitis", "Mitochondrial Encephalomyopathy (MELAS)"], "answer": "C", "answer_index": 2, "explanation": "Susac Syndrome is a rare autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is highly characteristic. It is often misdiagnosed as MS, but the presence of BRAO and callosal lesions (rather than callososeptal interface lesions) distinguishes it.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the clinical triad of subacute confusion (encephalopathy), bilateral hearing loss, and visual field deficits from branch retinal artery occlusions (BRAO), plus MRI 'snowball' lesions in the corpus callosum and periventricular white matter, CSF with mild pleocytosis and elevated protein but absent oligoclonal bands. These precisely match Susac Syndrome, distinguishing it from alternatives. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing selection of one best option. Main medical accuracy issue(s): None; the item's portrayal aligns with current understanding of Susac Syndrome as a rare microangiopathy with the described triad and characteristic callosal lesions, often mimicking MS but differentiated by BRAO and lack of oligoclonal bands. The rationale correctly notes distinctions from MS (e.g., callososeptal vs. snowball lesions). Alternatives are appropriately eliminated: MS typically has oligoclonal bands and lacks BRAO; CADASIL is genetic with lacunar infarcts but not this triad; primary CNS angiitis lacks specific BRAO/hearing loss; MELAS involves mitochondrial strokes but not snowball lesions. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the clinical triad of subacute confusion (encephalopathy), bilateral hearing loss, and visual field deficits from branch retinal artery occlusions (BRAO), plus MRI 'snowball' lesions in the corpus callosum and periventricular white matter, CSF with mild pleocytosis and elevated protein but absent oligoclonal bands. These precisely match Susac Syndrome, distinguishing it from alternatives. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing selection of one best option. Main medical accuracy issue(s): None; the item's portrayal aligns with current understanding of Susac Syndrome as a rare microangiopathy with the described triad and characteristic callosal lesions, often mimicking MS but differentiated by BRAO and lack of oligoclonal bands. The rationale correctly notes distinctions from MS (e.g., callososeptal vs. snowball lesions). Alternatives are appropriately eliminated: MS typically has oligoclonal bands and lacks BRAO; CADASIL is genetic with lacunar infarcts but not this triad; primary CNS angiitis lacks specific BRAO/hearing loss; MELAS involves mitochondrial strokes but not snowball lesions. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-008", "question": "A 29-year-old male who has sex with men presents with severe proctitis, tenesmus, and rectal bleeding. Rectal swab NAAT is positive for *Chlamydia trachomatis*. He was treated with Doxycycline 100 mg BID for 7 days with no improvement. His partner recently returned from Europe. Which of the following is the most appropriate management?", "options": ["Repeat Doxycycline 100 mg BID for 7 days", "Azithromycin 1 g single dose", "Ceftriaxone 500 mg IM single dose", "Extend Doxycycline 100 mg BID to complete a 21-day course", "Moxifloxacin 400 mg daily for 14 days"], "answer": "D", "answer_index": 3, "explanation": "Severe proctitis in MSM with a positive Chlamydia test should raise suspicion for Lymphogranuloma Venereum (LGV), caused by L1, L2, or L3 serovars. LGV requires a prolonged course of doxycycline (21 days) compared to non-LGV chlamydia (7 days). Standard treatment failure and severe symptoms (bleeding/tenesmus) strongly support a diagnosis of LGV.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include MSM status, severe proctitis with tenesmus and rectal bleeding, positive Chlamydia trachomatis NAAT, no improvement after 7-day doxycycline, and partner's recent travel from Europe (where LGV is endemic). These strongly suggest lymphogranuloma venereum (LGV) due to invasive serovars, requiring prolonged treatment. The question asks for the most appropriate management of suspected LGV chlamydial proctitis after initial treatment failure. Discriminating findings imply LGV over standard chlamydia: symptom severity, treatment non-response, and risk factors. Keyed answer D (extend doxycycline to 21 days) fits CDC guidelines for LGV. Alternatives: A repeats inadequate duration; B uses azithromycin, inferior for LGV; C targets gonorrhea, not indicated; E employs moxifloxacin, a second-line option not preferred. No main logical issues; stem allows unique discrimination without contradictions or underspecification, as presumptive LGV treatment is standard without serovar typing. No main medical accuracy issues; aligns with current CDC/WHO standards for LGV management in high-risk cases. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include MSM status, severe proctitis with tenesmus and rectal bleeding, positive Chlamydia trachomatis NAAT, no improvement after 7-day doxycycline, and partner's recent travel from Europe (where LGV is endemic). These strongly suggest lymphogranuloma venereum (LGV) due to invasive serovars, requiring prolonged treatment. The question asks for the most appropriate management of suspected LGV chlamydial proctitis after initial treatment failure. Discriminating findings imply LGV over standard chlamydia: symptom severity, treatment non-response, and risk factors. Keyed answer D (extend doxycycline to 21 days) fits CDC guidelines for LGV. Alternatives: A repeats inadequate duration; B uses azithromycin, inferior for LGV; C targets gonorrhea, not indicated; E employs moxifloxacin, a second-line option not preferred. No main logical issues; stem allows unique discrimination without contradictions or underspecification, as presumptive LGV treatment is standard without serovar typing. No main medical accuracy issues; aligns with current CDC/WHO standards for LGV management in high-risk cases. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-009", "question": "A 70-year-old man is evaluated for macrocytic anemia (MCV 105), thrombocytopenia, and recurrent inflammation of the ear and nose cartilage. He also has pulmonary infiltrates. Bone marrow biopsy demonstrates hypercellularity with vacuolization of myeloid and erythroid precursor cells. Genetic sequencing identifies a somatic mutation in *UBA1*. What is the diagnosis?", "options": ["Relapsing Polychondritis", "Myelodysplastic Syndrome (MDS)", "VEXAS Syndrome", "Sweet Syndrome", "Granulomatosis with Polyangiitis"], "answer": "C", "answer_index": 2, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in *UBA1*. It connects inflammatory features (polychondritis, vasculitis, infiltrates) with hematologic features (macrocytic anemia, vacuoles in marrow precursors). While it mimics relapsing polychondritis, the presence of marrow vacuoles and the *UBA1* mutation defines VEXAS.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old man with macrocytic anemia (MCV 105), thrombocytopenia, recurrent ear/nose cartilage inflammation, pulmonary infiltrates, bone marrow hypercellularity with vacuolization of myeloid/erythroid precursors, and somatic UBA1 mutation. These collectively point to VEXAS syndrome, characterized by inflammatory (chondritis, infiltrates) and hematologic (anemia, vacuoles) features linked to UBA1 mutations. The question asks for the diagnosis implied by this constellation, especially the pathognomonic UBA1 mutation and marrow vacuoles. Keyed answer C (VEXAS) fits precisely without assumptions. Alternatives: A (Relapsing Polychondritis) explains chondritis but lacks hematologic/vacuole/UBA1 elements; B (MDS) covers anemia/thrombocytopenia but not inflammation/UBA1; D (Sweet Syndrome) involves neutrophilic infiltrates but not chondritis/marrow vacuoles; E (Granulomatosis with Polyangiitis) may cause infiltrates/chondritis but misses UBA1/marrow specifics. No main logical issues; stem allows clear discrimination of one best option. No main medical accuracy issues; aligns with current literature on VEXAS as a monogenic autoinflammatory disorder mimicking other conditions but defined by UBA1. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old man with macrocytic anemia (MCV 105), thrombocytopenia, recurrent ear/nose cartilage inflammation, pulmonary infiltrates, bone marrow hypercellularity with vacuolization of myeloid/erythroid precursors, and somatic UBA1 mutation. These collectively point to VEXAS syndrome, characterized by inflammatory (chondritis, infiltrates) and hematologic (anemia, vacuoles) features linked to UBA1 mutations. The question asks for the diagnosis implied by this constellation, especially the pathognomonic UBA1 mutation and marrow vacuoles. Keyed answer C (VEXAS) fits precisely without assumptions. Alternatives: A (Relapsing Polychondritis) explains chondritis but lacks hematologic/vacuole/UBA1 elements; B (MDS) covers anemia/thrombocytopenia but not inflammation/UBA1; D (Sweet Syndrome) involves neutrophilic infiltrates but not chondritis/marrow vacuoles; E (Granulomatosis with Polyangiitis) may cause infiltrates/chondritis but misses UBA1/marrow specifics. No main logical issues; stem allows clear discrimination of one best option. No main medical accuracy issues; aligns with current literature on VEXAS as a monogenic autoinflammatory disorder mimicking other conditions but defined by UBA1. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is determining the recommended management per NCCN guidelines for a 35-year-old woman desiring fertility with Stage IA1 cervical squamous cell carcinoma featuring extensive LVSI. Key stem clues: 2 mm depth of invasion, 5 mm horizontal spread (confirming IA1), extensive LVSI, negative margins, no lymphadenopathy on imaging, and fertility desire. These drive a unique best answer by highlighting the need for more aggressive treatment due to LVSI risk while preserving fertility. The most likely next step is radical trachelectomy with pelvic lymph node assessment to address metastatic potential. Keyed answer B fits perfectly, aligning with NCCN recommendations for IA1 with LVSI in fertility-preserving scenarios, assuming standard staging. Alternatives: A is insufficient without LN assessment; C overlooks LVSI risk; D sacrifices fertility; E is not preferred for early-stage disease and impairs fertility. No main logical issues; stem is consistent and specifies details allowing discrimination. No main medical accuracy issues; consistent with current NCCN guidelines on cervical cancer management, emphasizing LVSI as a risk factor necessitating nodal evaluation. Minimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is determining the recommended management per NCCN guidelines for a 35-year-old woman desiring fertility with Stage IA1 cervical squamous cell carcinoma featuring extensive LVSI. Key stem clues: 2 mm depth of invasion, 5 mm horizontal spread (confirming IA1), extensive LVSI, negative margins, no lymphadenopathy on imaging, and fertility desire. These drive a unique best answer by highlighting the need for more aggressive treatment due to LVSI risk while preserving fertility. The most likely next step is radical trachelectomy with pelvic lymph node assessment to address metastatic potential. Keyed answer B fits perfectly, aligning with NCCN recommendations for IA1 with LVSI in fertility-preserving scenarios, assuming standard staging. Alternatives: A is insufficient without LN assessment; C overlooks LVSI risk; D sacrifices fertility; E is not preferred for early-stage disease and impairs fertility. No main logical issues; stem is consistent and specifies details allowing discrimination. No main medical accuracy issues; consistent with current NCCN guidelines on cervical cancer management, emphasizing LVSI as a risk factor necessitating nodal evaluation. Minimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]